Value Based Care

Putting a Price on Exercise After Colon Cancer Treatment

Putting a Price on Exercise After Colon Cancer Treatment

George Padron
Oncology Care, GI Cancers, Managed Care, Value Based Care | Aug 4, 2026
A JCO cost-utility analysis of the CHALLENGE trial found a structured exercise program after colon cancer chemotherapy was both less costly and more effective.
AI for Managed Care Administration: Enhancement or Replacement? (Part 2)Play Video

AI for Managed Care Administration: Enhancement or Replacement? (Part 2)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Aug 3, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines. (Part 2)
Vessel Pattern, Not Just Stenosis, Predicted Angina Relief From Stenting

Vessel Pattern, Not Just Stenosis, Predicted Angina Relief From Stenting

George Padron
Specialty Medicine, Cardiology, Managed Care, Value Based Care | Jul 28, 2026
An ORBITA-2 analysis in JACC found focal coronary disease predicted far greater placebo-controlled angina relief from PCI than diffuse disease.
AI for Managed Care Administration: Enhancement or Replacement? (Part 1)Play Video

AI for Managed Care Administration: Enhancement or Replacement? (Part 1)

George Padron
Podcasts, Healthcare Systems & Business, Digital Health & AI, Prior Authorization, Value Based Care | Jul 27, 2026
Dr. Randy Vogenberg discusses integrating AI into managed care, focusing on clinical pathways and expert guidelines.
In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

In Standard-Risk Myeloma, Two Years of Maintenance Equals Indefinite Therapy

George Padron
Oncology Care, Hematologic Malignancies, Access & Affordability, Drug Pricing & Out-of-Pocket, Managed Care, Value Based Care | Jul 23, 2026
In standard-risk myeloma without an up-front transplant, stopping lenalidomide maintenance at 2 years matched indefinite therapy on survival, with fewer harms.
Medication Burden Climbs After 75 in Patients With Steatotic Liver Disease

Medication Burden Climbs After 75 in Patients With Steatotic Liver Disease

Sonia Reyes
Specialty Medicine, GI & Hepatology, Managed Care, Value Based Care | Jul 22, 2026
An NHANES analysis found polypharmacy in older adults with MASLD rises sharply after age 75, raising deprescribing and goal-concordant care questions for payers.
Load More
Only Healthcare Today Covering Clinical Healthcare, Access and Cost

Only Healthcare Today
Covering Clinical Healthcare, Access and Cost

1 Hewitt Square, Suite 139
East Northport, NY 11731

Who We Are


About Us Editorial Policy Contributors & Partners

Connect


Contact Us Work With Us Advertising Terms of Use Privacy Policy